Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Université de Montréal currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units. This 1 to 1 ratio between actions, examiners, and art units indicates a highly individualized prosecution path for each pending application.
The busiest examiner for the university is HAVLIN, ROBERT H, who is responsible for 1 pending office action. Since there are 2 distinct examiners for the active matters, the workload is split equally. This means that each examiner's decisions will impact exactly half of the current pending portfolio.
The involvement of 2 distinct art units for the pending office actions suggests that the university's Biotechnology & Pharmaceuticals filings are technically diverse. Practitioners should be prepared to address the specific requirements of the assigned art units. With 2 distinct examiners involved, the university faces separate sets of examination styles and timelines, with 1 examiner assigned per case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.4% |
| REGLAS, GILLIAN CHELSEA | 1 | 30.2% | +41.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430652 | Use of Haploid Embryonic Cells to Generate Offspring with Predetermined Genomes | REGLAS, GILLIAN CHELSEA | 7d |
| 18826736 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | COUGHLIN, MATTHEW P | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18826736 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | COUGHLIN, MATTHEW P | — | DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 17430652 | Use of Haploid Embryonic Cells to Generate Offspring with Predetermined Genomes | REGLAS, GILLIAN CHELSEA | 1632 | §103 | Final Rejection | 7d | Pending | Aug 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial